DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Jung, H. (Department of Bio and Brain Engineering. KAIST)
Kim, H. S. (Division of Hematology/Oncology. Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine)
Kim, J. Y. (Department of Bio and Brain Engineering. KAIST)
Sun, J. M. (Division of Hematology/Oncology. Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine)
Ahn, Jin Seop (Division of Hematology/Oncology. Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine)
Ahn, M. J. (Division of Hematology/Oncology. Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine)
Park, K. (Division of Hematology/Oncology. Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine)
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Lee, S. H. (Department of Health Sciences and Technology. Samsung Advanced Institute of Health Science and Technology. Sungkyunkwan University)
Choi, J. K. (Penta Medix Co.. Ltd.)
Universitat Autònoma de Barcelona

Data:	2019
Resum:	Mitotic cell division increases tumour mutation burden and copy number load, predictive markers of the clinical benefit of immunotherapy. Cell division correlates also with genomic demethylation involving methylation loss in late-replicating partial methylation domains. Here we find that immunomodulatory pathway genes are concentrated in these domains and transcriptionally repressed in demethylated tumours with CpG island promoter hypermethylation. Global methylation loss correlated with immune evasion signatures independently of mutation burden and aneuploidy. Methylome data of our cohort (n = 60) and a published cohort (n = 81) in lung cancer and a melanoma cohort (n = 40) consistently demonstrated that genomic methylation alterations counteract the contribution of high mutation burden and increase immunotherapeutic resistance. Higher predictive power was observed for methylation loss than mutation burden. We also found that genomic hypomethylation correlates with the immune escape signatures of aneuploid tumours. Hence, DNA methylation alterations implicate epigenetic modulation in precision immunotherapy.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Aneuploidy ; Biomarkers, Tumor ; Cell Proliferation ; CpG Islands ; DNA Copy Number Variations ; DNA Methylation ; Epigenesis, Genetic ; Gene Expression Regulation, Neoplastic ; Humans ; Mutation Rate ; Neoplasms ; Promoter Regions, Genetic ; Tumor Escape
Publicat a:	Nature communications, Vol. 10 Núm. 1 (january 2019) , p. 4278, ISSN 2041-1723

DOI: 10.1038/s41467-019-12159-9
PMID: 31537801

12 p, 3.6 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Institut de Recerca contra la Leucèmia Josep Carreras
Articles > Articles de recerca
Articles > Articles publicats